# Developing an Antimicrobial Strategy for Sepsis in Malawi

-

Thesis submitted in accordance with the requirements of the Liverpool School of Tropical Medicine for the degree of Doctor in Philosophy by Joseph Michael Lewis

August 2019

# Contents

# List of Tables

# List of Figures

# Preface

Placeholder

# Chapter 1

# Introduction

Placeholder

## 1.1 Chapter Overview

## 1.2 Sepsis in sub-Saharan Africa

### 1.2.1 Search strategy

### 1.2.2 Defining sepsis

### 1.2.3 Applicability of sepsis-3 definitions in sub-Saharan Africa

### 1.2.4 Sepsis epidemiology in sub-Sahara Africa

#### 1.2.4.1 Incidence

#### 1.2.4.2 Risk factors: the sepsis population in sub-Saharan Africa

#### 1.2.4.3 Outcomes

### 1.2.5 Sepsis aetiology in sub-Saharan Africa

#### 1.2.5.1 Bacterial zoonoses, Rickettsioses and arboviruses

#### 1.2.5.2 HIV opportunistic infections: PCP, histoplasmosis and cryptococcal disease

### 1.2.6 Sepsis management

#### 1.2.6.1 Early goal directed therapy

#### 1.2.6.2 Evidence to guide antimicrobial therapy in sSA

#### 1.2.6.3 Evidence to guide intravenous fluid therapy in sub-Saharan Africa

## 1.3 ESBL-E in sub-Saharan Africa

### 1.3.1 Search strategy

### 1.3.2 Introduction: definition and classification of ESBL-E

### 1.3.3 Global molecular epidemiology of ESBL-E: an overview

#### 1.3.3.1 1980s-1990s: First identificatiom of ESBL in nosocomial pathogens

#### 1.3.3.2 1990s-2010s: Emergence and globalisation of CTX-M

# Chapter 2

# Methods

Placeholder

## 2.1 Chapter Overview

## 2.2 Study site

### 2.2.1 Malawi

### 2.2.2 Queen Elizabeth Central Hospital

### 2.2.3 Participating Laboratories

#### 2.2.3.1 Malawi-Liverpool-Wellcome Clinical Research Programme

#### 2.2.3.2 Malawi College of Medicine Tuberculosis Laboratory

#### 2.2.3.3 Wellcome Trust Sanger Institute

## 2.3 Clinical Study

### 2.3.1 Entry Criteria

### 2.3.2 Study Visits and Patient Sampling

#### 2.3.2.1 Enrollment assessment and first six hours

#### 2.3.2.2 Subsequent visits

#### 2.3.2.3 Blood, urine, and stool, sputum and CSF collection

#### 2.3.2.4 Imaging: chest x-ray and ultrasound scanning

### 2.3.3 Outcomes and sample size calculations

## 2.4 Diagnostic Laboratory Procedures

### 2.4.1 Point of care diagnostics

### 2.4.2 Laboratory diagnostics

#### 2.4.2.1 Haematology and biochemistry

#### 2.4.2.2 Aerobic blood and CSF culture

#### 2.4.2.3 Mycobacterial blood culture

# Chapter 3

# *Mycobacterium tuberculosis* BSI: an IPD meta analysis

# Chapter 4

# A clinical and microbiological description of sepsis in Blantyre, Malawi

Placeholder

## 4.1 Chapter overview

## 4.2 Introduction and chapter aims

## 4.3 Aims and Methods

## 4.4 Results

### 4.4.1 Study population

### 4.4.2 Symptoms and health-seeking behaviour

### 4.4.3 Admission physiology and laboratory investigations

### 4.4.4 Aetiology

### 4.4.5 Treatment

### 4.4.6 Outcome

### 4.4.7 Determinants of mortality

## 4.5 Discussion

### 4.5.1 Demographics and outcome: significant longer-term mortality

### 4.5.2 Aetiology: TB dominates as a cause of sepsis

### 4.5.3 Determinants of 28-day mortality: an expanded role for TB therapy?

### 4.5.4 Limitations

## 4.6 Conclusions and further work

## 4.7 Appendix

# Chapter 5

# Longitudinal ESBL-E carriage in Malawian adults in health and disease

Placeholder

## 5.1 Chapter Overview

## 5.2 Introduction and chapter aims

## 5.3 Methods

## 5.4 Results

### 5.4.1 Study population

## 5.5 Discussion

### 5.5.1 Limitations

## 5.6 Conclusions and further work

# Chapter 6

# Whole genome sequencing of ESBL *E. coli* carriage isolates

Placeholder

## 6.1 Chapter overview

## 6.2 Methods

### 6.2.1 Bioinformatic pipeline

### 6.2.2 Global *E. coli* collection

### 6.2.3 Statistical analysis

## 6.3 Results

### 6.3.1 Samples and quality control

### 6.3.2 Phylogroup, MLST and core genome phylogeny of study isolates

### 6.3.3 Study isolates in a global context

### 6.3.4 Antimicrobial resistance determinants

#### 6.3.4.1 $\beta$-lactam resistance

#### 6.3.4.2 Quinolone resistance

#### 6.3.4.3 Aminoglycoside resistance

#### 6.3.4.4 Chloramphenicol, co-trimoxazole, tetracycline and other resistance determinants

#### 6.3.4.5 Clustering and lineage association of AMR determinants

### 6.3.5 Plasmid replicons

### 6.3.6 Testing metadata associations: SNP distance, hierBAPS sequence clusters and ESBL-clusters

#### 6.3.6.1 Hierarchical BAPS clustering of core gene pseudosequences

#### 6.3.6.2 ESBL-clusters

#### 6.3.6.3 Assessing for healthcare-associated lineages

#### 6.3.6.4 Assessing for within-patient conservation of lineage or MGE

## 6.4 Discussion

# Chapter 7

# Gut mucosal carriage of ESBL-E in Blantyre, Malawi

# References